Trump wavers on nominee for drug czar

Report reveals Pennsylvania lawmaker steered legislation that favored pharmaceutical companies

Washington — President Donald Trump said Monday he will declare a national emergency next week to address the opioid epidemic and declined to express confidence in Rep. Tom Marino, R-Pa., his nominee for drug czar, in the wake of revelations that the lawmaker helped steer legislation making it harder to act against giant drug companies.

Trump’s remarks came amid widespread reaction across the political spectrum to a Washington Post/“60 Minutes” investigation that Marino helped guide legislation that sailed through Congress last year with virtually no opposition.

Trump said “we’re going to be looking into” the investigation, while many Democrats and at least one Republican called for either modification or outright repeal of the law. Democrats also called on Trump to drop Marino as his pick to lead the Office of National Drug Control Policy.

Speaking in the White House Rose Garden, Trump defended Marino as “a very early supporter of mine” and “a great guy.” He said he had seen the reporting in question and that the White House would be reviewing the information.

Trump said he will have a “major announcement, probably next week” about how his administration plans to tackle opioid addiction in the United States, a “massive problem” that he wants to get “absolutely right.”

“This country and, frankly, the world has a drug problem,” he said. “We’re going to do something about it.”

Asked by a reporter whether he would be declaring the epidemic a national emergency, as he first promised in August but has not yet done, Trump said, “We’re going to be doing that next week.”

A presidential declaration could allow the administration to remove some bureaucratic barriers and waive some federal rules governing how states and localities respond to the drug epidemic. One such rule restricts where Medicaid recipients can receive addiction treatment.

The president also said he had not yet spoken with Marino about the Post/“60 Minutes” report, but if he determines

that Marino’s work was detrimental to the administration’s goal of combating opioid addiction, “I will make a change.”

On Monday, Democrats called on Trump to quickly discard Marino in the wake of the report, which detailed how a targeted lobbying effort helped weaken the Drug Enforcement Administration’s ability to go after drug distributors, even as opioid-related deaths continue to rise.

Senate Minority Leader Charles Schumer, D-N.Y., said nominating the Pennsylvania lawmaker for drug czar “is like putting the wolf in charge of the hen’s house. The American people deserve someone totally committed to fighting the opioid crisis, not someone who’s labored on behalf of the drug industry.”

Sen. Joe Manchin, D-W.Va., also said he was “horrified” to read details of the investigation and called for Trump to drop Marino because “there’s no way that in having the title of the drug czar that you’ll be taken seriously or effectively

by anyone in West Virginia and the communities that have been affected by this knowing that you were involved in something that had this type of effect.”

Marino was first floated as a potential drug czar last spring, but withdrew from consideration, citing a family illness. The White House formally nominated him for the post in September. The Senate Judiciary Committee has yet to set a date for his confirmation hearing because Marino has not sent back answers to a written questionnaire that all nominees must complete before a hearing, a spokesman said. Members of the committee also didn’t immediately return requests for comment on the nomination or declined to comment. Ultimately, Marino could be confirmed by the Senate with a simple majority vote.

Across Capitol Hill, congressional Democrats and at least one Republican, Rep. Brian Fitzpatrick, Pa., announced plans to address the investigation’s findings.

Sen. Claire McCaskill, D-Mo., said Monday that she would introduce legislation that would repeal the Ensuring Patient Access and Effective Drug Enforcement Act of 2016. The law, she said, “has significantly affected the government’s ability to crack down on opioid distributors that are failing to meet their obligations and endangering our communities.”

McCaskill, as the top Democrat on the Homeland Security and Governmental Affairs Committee, has used her perch to probe opioid manufacturers, and is pushing them for sales and marketing materials, studies of potential addictions and whether the firms are donating to third-party advocacy groups that champion their work. It was unclear Monday afternoon how much support McCaskill’s bill would receive and whether it would ever be taken up for a vote in the GOP-controlled House and Senate.

Sen. Richard Blumenthal, D-Conn., also called for Trump to withdraw Marino’s nomination,

saying in an interview that “The head of that office is supposed to be a watchdog, not a lapdog. He obviously is much more an industry representative than he is a whistleblower or watchdog.”

“It will be ugly” if Trump continues with the nomination, Blumenthal said.

In the House, at least two Democrats — Reps. Gerald Connolly, Va., and Kyrsten Sinema, Ariz. — were working on bills that would rescind the thresholds put in place by Marino’s bill and give the DEA more authority to suspend a distributor’s license. Sinema is partnering with Fitzpatrick.

Rep. Peter Welch, D-Vt., an original cosponsor of Marino’s legislation, said he supported the bill on behalf of a small drug distributor in Burlington, Vt., that had concerns about how the DEA worked with drug companies. He called on the Oversight and Energy and Commerce committees to hold hearings on the legislation that would include testimony from current and former DEA officials.

One of Marino’s home-state senators, Sen. Robert Casey, D-Pa., is withholding judgment on Marino’s nomination, but a spokesman for the senator said that he believes the congressman “should be asked to address this matter.” Casey also believes that the legislation Marino backed “should be repealed immediately and DEA’s authority to hold drug distributors to tough standards should be restored,” said spokesman John Rizzo.

Manchin, McCaskill and Casey face re-election next year in rural states that Trump won. Despite their concerns, they did not oppose the legislation when it passed in the Senate last year by unanimous consent. McCaskill was away from Congress for three months for breast cancer treatment when the bill passed last year.

Manchin said in the interview that his aides responsible for tracking drug policy had raised concerns about Marino’s legislation as it worked its way through Congress last year.